Using telemedicine to improve peritoneal dialysis outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop a national database for patients undergoing peritoneal dialysis (PD) in China, utilizing a telemedicine-assisted platform. By enrolling 7,000 adult patients with end-stage renal disease, the study will analyze survival rates and identify risk factors associated with patient outcomes. Data will be collected from 27 hospitals across various regions in China, focusing on clinical characteristics and PD practices. The goal is to enhance the understanding of PD outcomes and improve patient care through robust data analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* End-stage renal disease patients receiving maintenance peritoneal dialysis;
* more than 14 years old

Exclusion Criteria:

* receiving temporary PD due to acute kidney injury
* loss to follow up without any outcomes recorded.

Where it's running

• The second affiliated hospital of Anhui Medical University
  Hefei, Anhui, China Recruiting
• Peking University First Hospital
  Beijing, Beijing, China Recruiting
• People's Hospital of Gansu Province
  Lanzhou, Gansu, China Recruiting
• Peking University Shenzhen Hospital
  Shenzhen, Guangdong, China Recruiting
• Cangzhou central hospital
  Cangzhou, Hebei, China Recruiting
• People's hospital of Cangzhou
  Cangzhou, Hebei, China Recruiting

Study contacts

• Study coordinator: Jie Dong, MD,Ph.D.
• Email: jie.dong@bjmu.edu.cn
• Phone: 086-010-83572388

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oral Bisacodyl Before Catheter Insertion to Help Peritoneal Dialysis

  This study tests whether giving a laxative before Tenckhoff catheter insertion helps keep the catheter flowing smoothly for people starting peritoneal dialysis.

  Recruiting Phase 4 Chinese University of Hong Kong · Kwai Chung, Kowloon and 5 other locations · NCT07351357

• Thiazide diuretics to lower blood pressure in people on peritoneal dialysis

  This trial will try a daily 25 mg hydrochlorothiazide pill to lower blood pressure in people on peritoneal dialysis whose blood pressure is above 140/90.

  Recruiting Phase 4 Chinese University of Hong Kong · Hong Kong · NCT07271420

• Nalfurafine orally disintegrating tablets for moderate-to-severe itching in people on peritoneal dialysis

  The trial will try nalfurafine orally disintegrating tablets to reduce moderate-to-severe itching in adults on peritoneal dialysis.

  Recruiting Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT07098351

• Amino acid peritoneal dialysis for adults with diabetes

  This study will try an amino acid–based peritoneal dialysis solution in adults with diabetes on peritoneal dialysis to see if their hemoglobin A1c changes after 90 days.

  Recruiting The People's Hospital of Gaozhou · Gaozhou, Guangdong · NCT07077538

• High- versus low-dose iron treatment for adults on peritoneal dialysis (PALaDIN)

  This project will see if higher-dose versus lower-dose iron treatment helps adults on peritoneal dialysis with iron-deficiency anaemia keep their iron and haemoglobin levels more stable.

  Recruiting Phase 3 Hull University Teaching Hospitals NHS Trust · Hull, East Riding Of Yorkshire · NCT06884280

• Mobile training system for patients on peritoneal dialysis

  This study tests a mobile training program to help people on peritoneal dialysis improve their skills and knowledge, especially for those who have been on dialysis for a while or just got over an infection.

  Recruiting China Medical University Hospital · Taichung · NCT06876987

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.